The role of hematopoietic SCT (HSCT) in mantle cell lymphoma (MCL) remains controversial. Most studies that support the utility of this approach were small phase II single-institution studies with highly selected patient populations. Furthermore, recent evidence suggesting initial observation as opposed to immediate therapy in MCL, coupled with the availability of newer therapeutic agents, complicates the role of HSCT and argues for conducting large phase III studies. In this review, we discuss the limitation of current evidence and the lack of large definitive studies. We then analyze the data on HSCT in relapsed MCL and as a frontline approach propose applying the new prognostic index, MIPI (MCL International Prognostic Index), in the decision making.
Introduction
Mantle cell lymphoma (MCL) is a distinct clinicopathological subtype of B-cell non-Hodgkin's lymphoma that accounts for 8-10% of all lymphomas. 1, 2 It is associated with t(11;14)(q13;q32), a chromosomal abnormality that causes overexpression of cyclin D1. 3 This disrupts cell cycle regulation by increasing retinoblastoma protein phosphorylation, leading to the loss of its inhibitory effect on G1/S cellular transition phase. 4 The detection of cyclin D1 by immunohistochemistry is pathognomonic for MCL diagnosis and permits distinction of this disease from other lymphoproliferative disorders that might seem morphologically similar. 5 MCL cells co-express CD5 and CD20 but lack CD23 and CD10. Cells usually have bright IgM surface staining. 6 Recently, it has been proposed that a subset of MCL patients could have CD23 þ disease and that this may be associated with a better prognosis than CD23À cases. 7 This may explain in part why some MCL patients have an indolent course.
Recently, a new prognostic model has been introduced by the German Lymphoma Study Group. 8 Hoster et al. 8 based the MIPI (MCL International Prognostic Index) on age, performance status, serum lactate dehydrogenase and leukocyte count. Patients are classified into low-, intermediate-and high-risk groups with widely disparate median OS durations. The median OS for the low-risk group, which comprised 44% of the entire studied cohort, was not reached at the time of that report. The median OS for 35% of patients who fell in the intermediate-risk group was 51 months. Finally, 21% were in the high-risk group with a median OS of 29 months. 8 Future studies are likely to incorporate this model to evaluate different treatment strategies.
Other important prognostic factors have been described. Morphologically, MCL with blastoid features carry the least favorable outcome. Some suggest that median survival in this subtype is o11 months as most patients present with high-grade features, BM infiltration and leukemic phase. On the molecular level, patients with mutated Ig variable heavy-chain gene carry a better outcome. In addition, Determann et al. 9 showed that the proliferation marker Ki-67 carries an adverse prognostic outcome even in patients treated with anti-CD20 antibodies, especially in those with 430% Ki-67. The major challenge remains how to incorporate the knowledge of adverse features into management decisions.
There is a lack of consensus as to the best frontline treatment strategy in MCL. Although some propose highdose chemotherapy with hematopoietic SCT (HSCT), 10, 11 others suggest that chemoimmunotherapy (CIT) with rituximab-based combinations is best. 12 Some have questioned the utility of rituximab in MCL and have suggested that rituximab is less effective. 13 To further complicate the question of the best frontline therapy, new chemotherapy agents have been introduced that are changing the approach to patients with MCL. approach in MCL was a logical step. Howard et al. 15 reported high response rates with R-CHOP (rituximab, CY, doxorubicin, VCR and prednisone) when given as frontline therapy for MCL, with 38 of 40 patients responding. However, responses were short lived with a median PFS of 16.6 months for all patients. Lenz et al. 16 confirmed superior response rates with R-CHOP when compared with CHOP in a randomized study, but found PFS to be comparable. The two studies suggested that different additional strategies were needed to prolong remission duration. In an effort to achieve these goals, the group at M.D. Anderson Cancer Center studied the dose-intensive chemotherapy regimen of hyper-CVAD (CY, VCR, doxorubicin and dexamethasone alternating with high-dose MTX and cytarabine) as an induction therapy before HSCT in 25 previously untreated patients. 17 The overall response (OR) rate was 93% before transplantation with 38% CR. The reported OS and EFS at 3 years were 92 and 72%, respectively. 17 The high response rate before HSCT in this trial made rituximab-hyper-CVAD the platform on which further studies were based. Romaguera et al. 12 reported on a phase II trial of rituximab with fractionated hyper-CVAD (R-hyperCVAD) alternating every 21 days with rituximab plus high-dose MTX-cytarabine for a total of 6-8 cycles.
The response rate was excellent with 87% CR among 97 enrolled patients. With a median follow-up of 40 months, the 3-year EFS and OS rates were 64 and 82%, respectively. However, no plateau was observed in either curve. Adverse effects were a concern because 5 patients died from acute toxicity, 4 patients developed treatment-related myelodysplasia or acute myeloid leukemia and 3 patients died while in remission. The treatment-related death rate was estimated at 8%. 12 An update of these results with a median follow-up of 4.8 years showed 5-year EFS and OS rates of 48 and 65%, respectively, with an impressive 7-year survival rate of 47% in patients with blastoid morphology. 18 However, these promising results could not be reproduced when the same regimen was used in a multiinstitutional Southwest Oncology Group trial. Among 49 patients, the OR and CR rates were 88 and 40%, respectively. 19 The 2-year PFS and OS rates of 62 and 76% were inferior to those reported by the M.D. Anderson group.
In an effort to maintain efficacy while reducing toxicity, Kahl et al. 20 eliminated the mid-treatment high-dose MTX and cytarabine in R-hyperCVAD while continuing the other agents. Among 22 patients with previously untreated MCL, the OR was 77% with a CR rate of 64%. Responding patients were allowed to continue on maintenance rituximab given weekly for 4 doses every 6 months for a total of 2 years. Responding patients receiving maintenance rituximab had a median PFS of 37 months and a median OS that was not reached. These results suggested that elimination of high-dose MTX and cytarabine did not affect efficacy but reduced treatment-related toxicity, as only two patients died during treatment. Table 1 summarizes the pivotal large phase II studies in MCL.
Although CIT seems to be effective in MCL as a frontline approach, incorporation of newer agents and/or other approaches seem to be essential to improve the overall outcome and to translate higher response rates into longer PFS and OS. In addition, reduction of treatmentrelated toxicity is also essential to improve the overall outcomes.
New chemotherapy agents
Bortezomib is a proteasome inhibitor that exerts an effect on cellular pathways that eventually lead to tumor cell apoptosis. 21 It was found to be active in relapsed MCL with an OR rate of 33% (CR 6%), median response duration of 9.2 months and a 1-year OS of 69%. 22 These results led to the approval of this agent by the Food and Drug Administration, allowing its investigation in the frontline setting. 23 Subsequently, most trials studied this drug in combination regimens given the aggressive nature of MCL. Belch et al. 24 reported a small phase II trial of 30 patients, 13 of whom were previously untreated. In this study, the reported OR of 46% was similar among previously treated and untreated patients with median response duration of 10 months. Kahl et al. 25 incorporated bortezomib into their modified R-hyperCVAD regimen. Painful neuropathy was the major toxicity requiring two dose reductions. Among 30 enrolled patients, OR rate was 90% with 70% CR. PFS and OS at 18 months were 73 and 97%, respectively. These results seem better than historic data suggesting improvement in responses and efficacy with bortezomib. However, only randomized trials with or without bortezomib can determine the true effect of adding this agent into frontline regimens.
Temsirolimus is an inhibitor of the mammalian target of rapamycin targeting the phosphatidyl inositol 3 kinase pathway. 26 This mechanism inhibits the translation of mRNA, including cyclin D1 mRNA, making this agent a sound therapeutic agent in MCL. Accordingly, investigators studied this agent in relapsed disease showing response rates in excess of 30% with CR of 3%. 27, 28 In fact, a phase III study suggested that this agent as monotherapy might be more effective than the investigator's choice in relapsed disease. 29 Other agents have shown promising activity in relapsed disease paving the way for frontline trials. Thalidomide and lenalidomide have shown modest activity in relapsed disease, suggesting possible enhanced activity in the frontline setting. [30] [31] [32] Rummel et al. 33 reported on the activity of bendamustine combined with rituximab in relapsed lowgrade lymphoma and MCL. Only 16 patients enrolled on that study had MCL histology, but the overall response rate of 75% (CR 50%) in this subset supported studying this agent in randomized trials. Herold et al. 34 replaced CY with bendamustine when they compared COP (CY, VCR and prednisone) with the BOP (bendamustine, VCR and prednisone) regimen in patients with indolent non-Hodgkin's lymphoma or MCL. The projected 5-year survival for responders reached statistical significance but other end points were similar between treatment groups. Despite the small size of this study (164 patients) and the different histologies, the results support the efficacy of bendamustine in the frontline setting and its safety when combined with other chemotherapeutic agents.
The availability of several agents with good activity in MCL makes the question of HSCT in this setting a vexing one. However, the relatively modest results with CIT in MCL, coupled with the improved HSCT techniques and safety, suggested that intensified treatment might have a role in this disease.
HSCT for relapsed MCL
On the basis of observations in large cell lymphoma, [35] [36] [37] several groups investigated high-dose therapy with HSCT in relapsed MCL. Vose et al. 38 evaluated the outcome of 40 relapsed patients who underwent autologous HSCT (auto-HSCT) between 1991 and 1998. With a median follow-up of 24 months for surviving patients (range 4-68 months), the 2-year OS was 65% and the 2-year EFS was 36%. In univariate analysis, characteristics predictive of poor EFS were blastic morphology and X3 previous chemotherapy regimens. In a multivariate analysis, the only factor associated with poor EFS was the number of previous chemotherapy regimens. Those patients who received X3 previous therapies had a 2-year EFS of 0%, and those who received o3 therapies had a 2-year EFS of 45% (P ¼ 0.004). This study showed that auto-HSCT prolonged remissions in relapsed MCL as long as the patients were not heavily pretreated. However, remissions in responding patients were not durable and no plateau on the survival curve was showed. 38 Incorporating I 131 -tositumomab (Bexxar) into the conditioning regimen of HSCT in relapsed MCL proved feasible, effective and potentially better than standard conditioning programs. Gopal et al. 39 reported on 16 patients who received I 131 -tositumomab with high-dose CY and etoposide conditioning with HSCT. The reported 3-year OS and PFS were 93 and 61%, respectively. Khouri et al. 17 reported impressive EFS of 92% at 3 years when hyper-CVAD was used as an induction program before HSCT, but the inclusion of some previously untreated patients complicates the interpretation of these results. Despite higher responses with these aggressive programs, relapse rates remained high, arguing in favor of examining allogeneic-HSCT (allo-HSCT) to harness graft vs lymphoma effects. To that extent, Robinson et al. 40 reported on behalf of the European Group for Blood and Bone Marrow Transplantation (EBMT) their experience with reducedintensity allo-HSCT. This HSCT was used in an attempt to minimize toxicity, given the older age expected in this patient population. The initial report showed a prohibitively high treatment-related mortality of 46% at 1 year and a poor 2-year OS of only 13%. 40 This analysis was later updated with 144 patients from 81 centers (median age 49 years) with a median time from diagnosis to SCT of 25 months. The median number of previous therapies received was 2 (range 1-5) and 43% of the patients had received previous auto-HSCT. 41 Importantly, at the time of HSCT, 100 patients had chemosensitive disease, 22 had chemoresistant disease and 22 had untested relapse. Of the 144 patients, 109 had a full matched sibling HSCT. TRM was 12% at 100 days but was estimated to be 35% at 1 year and 50% at 2 years. The OS was 55 and 31% at 1 and 2 years, respectively, with a PFS of 43 and 26%, respectively. 41 When analyzing factors that were associated with inferior outcome, poor performance status, refractory disease and HSCT before 2002 were adverse factors that affected outcome. 42 
Table 1
Pivotal frontline combination chemotherapy studies in MCL It is noteworthy that a one small study of 18 patients, in which hyper-CVAD was used as an induction regimen followed by reduced-intensity HSCT, reported a TRM of 0% at 100 days with EFS of 82% at 3 years. 43 Some patients achieved molecular remission, but the applicability of this approach requires further confirmation in larger studies.
These poor results suggest that allo-HSCT may be of limited benefit in patients with relapsed disease who have been extensively treated previously. Table 2 summarizes some important studies using auto-HSCT as a salvage therapy in relapsed MCL. Table 3 summarizes pivotal studies that analyzed allo-HSCT as a salvage approach.
HSCT in first remission
The recognized marginal benefit noted with autologous HSCT in relapsed patients paved the way to implement such strategy in patients attaining their first remission as a consolidative approach. Milpied et al. 44 performed highdose therapy and auto-SCT on 17 patients, of whom 10 were in their first PR. Although the combined analysis of all patients in this study showed a median OS of 48% at 4 years, those who were in their first PR did better than those who were in their second remission. Furthermore, patients who received TBI as part of their conditioning regimen did better than those who received chemotherapy alone. 44 Although this study showed an impressive OS, the patient population was heterogeneous with some receiving HSCT after their second CR. This observation suggested that HSCT in first CR might be superior but definitive conclusions required additional studies. The controversy of this approach was heightened when Freedman et al. 45 questioned the utility of HSCT in MCL after they retrospectively analyzed patients who had undergone this procedure in first CR or in relapse after showing chemosensitive disease. All 28 patients received a uniform ablative regimen with CY and TBI. In all, 20 patients had relapsed disease, whereas eight were treated with HSCT in their first remission (complete or partial) after CHOP induction chemotherapy. At the time of that report, 19 of 28 patients showed a relapse at a median time of 21 months. Of eight patients transplanted in first CR/PR, five have relapsed. Nine patients were in continuous CR with a median follow-up time of 24 months. DFS and OS were estimated at 31 and 62% at 4 years. The researchers suggested that the lack of plateau with a median follow-up time of 24 months argues against recommending HSCT as a treatment strategy. 45 However, other studies showed more robust results. Khouri et al. 17 reported on 33 patients in first CR who underwent high-dose therapy and auto-HSCT as a consolidative approach after hyper-CVAD. At a median follow-up of 49 months, OS was 77% and PFS was 43%. Additional small phase II studies showed variable results with a notion that implementing high-dose therapy and auto-HSCT in first CR is likely superior when compared with historical controls. Vigouroux et al. 47 Murali et al. 48 described 21 patients with MCL who received auto-HSCT as part of the primary treatment strategy. Of the total, 16 patients were in CR1 and 5 in PR1 at the time of HSCT. At the time of that report, 17 patients were in continuous CR with four relapses and no transplant-related deaths. With a median follow-up of 54 months from HSCT, the 5-year PFS and OS were 73 and 76%, respectively. This long follow-up with favorable outcome helped the case for autologous transplantation in first CR in MCL.
Another important phase II study was recently reported by Evens et al.
11 who used an intensive multiagent chemotherapeutic regimen (CY, teniposide, doxorubicin and prednisone (CTAP) alternating with VCR and highdose MTX and cytarabine (VMAC)) in newly diagnosed MCL. After 4-6 cycles of CTAP/VMAC induction, patients aged p65 years proceeded to consolidative auto-HSCT, whereas patients aged p55 years who had an HLAidentical sibling received allo-HSCT (BU/CY conditioning for both). In all, 25 untreated MCL patients were enrolled between 1997 and 2002 with an OR of 74% after induction chemotherapy. Seventeen patients received HSCT (autologous-13/allogeneic-4). On intent-to-treat analysis, ORR for patients who received consolidative HSCT was 100% (CR 76%). Therapy was well tolerated with 4% treatmentrelated mortality (including HSCT). The 5-year EFS and OS for all patients were 35 and 50%, respectively. Furthermore, at 66-month median follow-up, the 5-year EFS and OS for patients who received consolidative auto-HSCT were 54 and 75%, respectively. Patients who received auto-HSCT had improved outcomes when compared with no auto-HSCT (EFS P ¼ 0.001; OS P ¼ 0.0002).
11
The largest analysis on the benefit of HSCT in MCL was reported by Vandenberghe et al. 49 who reviewed data and outcome on 195 patients enrolled on the European and American BMT registries with a median follow-up of 3.9 years. The 2-year OS at 2 and 5 years were 76 and 50%, respectively, with PFS of 55 and 33% at these time points. Disease status at transplant was the most significant factor affecting survival. Patients with chemosensitive disease but not in CR1 were 2.99 times (Po0.001) more likely to die than patients transplanted in CR1. This large analysis showed that patients transplanted in first CR fared better than those transplanted in subsequent remissions, thus arguing for early HSCT. 49 Once rituximab became available, it became a standard addition to the induction regimens or a part of the transplant preparative program. It proved to be very effective in MCL and suggested an improved outcome when used. 47 Gianni et al. 50 used high-dose rituximab as part of the conditioning regimen in 28 previously untreated patients. This approach resulted in OS and EFS of 89 and 79%, respectively, at 54 months. 50 Furthermore, Dreger et al. 51 showed that patients who received rituximab as part of the HSCT conditioning regimen had better outcomes when compared with historical controls who did not receive rituximab. The only randomized trial suggesting an advantage for early HSCT was reported by Dreyling et al. 52 on behalf of the European MCL network. In that study, 122 patients were randomized after responding to a CHOP-like regimen to either maintenance IFN thrice a week or to intensification with high-dose chemotherapy and HSCT. Thus, 60 patients received maintenance IFN whereas 62 underwent HSCT. Patients in the HSCT arm had a better PFS when compared with IFN (39 vs 17 months, P ¼ 0.01). OS was similar at 3 years (83 vs 77%). 52 This randomized study confirmed the observation of Mangel et al. 53 who compared autografted MCL patients with matched historic controls and showed better PFS (89 vs 29% at 3 years, Po0.00001) and OS (88 vs 55%, P ¼ 0.06) with HSCT.
A recent study reported by Geisler et al. 10 showed excellent long-term results and suggested a possible change in the natural history of the disease. This Nordic MCL2 trial treated 160 consecutive MCL patients with a doseintensified CIT combination using R-CHOP alternating with rituximab-cytarabine. Responding patients underwent high-dose chemotherapy followed by HSCT, using stem cells purged in vivo with rituximab. OR and CR were 96 and 54%, respectively. The 6-year OS, EFS and PFS rates were 70, 66 and 56%, respectively, with no relapses occurring after 5 years, suggesting a possible plateau. 10 The lack of relapse after 5 years is intriguing and suggests for the first time a possible plateau in MCL arguing in favor of this approach.
Both studies report a positive effect of HSCT. The lack of an OS advantage in the MCL1 trial could be explained by the small sample size that would lack the power to detect such a small difference and to the lack of rituximab as part of the induction or maintenance programs. The impressive results of MCL2 study might have been affected by treating every enrolled patient with rituximab-based therapy and the fact that all patients also received cytarabine that might have overcome resistant clones that survived the initial induction program.
These studies suggest that early HSCT is beneficial. However, it is unclear whether all patients benefit to a similar extent and this is an area of future research studies. Table 4 summarizes pivotal studies that analyzed HSCT in first CR.
Practical questions about HSCT in MCL
The role of rituximab Although rituximab has clearly shown activity in MCL as a single agent, such efficacy is less pronounced in this disease compared with other lymphoid malignancies. Responses range from 25 to 30% even in previously untreated patients with a median duration of response at 6 months. 54, 55 When combined with chemotherapy, it enhances chemotherapy responses, although OS advantage was lacking in randomized studies. 15, 16 Although some have questioned the utility of rituximab in MCL, 13 a recent meta-analysis that investigated seven randomized studies in low-grade Transplantation in mantle cell lymphoma C Nabhan et al lymphoma and MCL suggested that rituximab plus chemotherapy may provide better OS when compared with chemotherapy alone. 56 We argue in favor of using rituximab as part of the induction program or as a maintenance approach if chemotherapy alone was used as induction. 57 The role of maintenance rituximab after HSCT is controversial and studies are required to better identify its role in that setting.
Can MCL patients be observed? Recently Martin et al. 58 retrospectively studied 31 patients with a median age of 58 who were observed for at least 3 months rather than immediate therapy. Better performance status and lower-risk standard International Prognostic Index scores were more commonly present in those undergoing observation. Although time to treatment did not predict OS in a multivariate analysis, the survival profile of this observation group was statistically superior to that of the early treatment group (not reached vs 64 months, P ¼ 0.004), arguing that in selected asymptomatic patients with MCL, deferred initial treatment ('watch and wait') is an acceptable management approach.
The same group also had previously identified a population of MCL patients who were treated heterogeneously with a median OS of 7.1 years. Adequate treatment information was available for 75 patients. Only five were treated upfront with R-hyper-CVAD or auto-HSCT whereas an additional four patients received one of these regimens subsequently. Treatment type had no significant effect on OS. Both reports suggest that outcomes with standard approaches or deferred therapy could yield similar survival to that achieved with more intensive approaches. It remains challenging to select which patients are suitable for less intensive intervention.
Both reports, however, represent retrospective analyses that need to be validated in prospective studies. Although the 'watch and wait' policy is intriguing, we advocate immediate therapy for all patients with newly diagnosed MCL. Observation can be considered in those older unfit patients who have low-risk prognostic score, are asymptomatic and have low-volume disease. Ideally, such patients should be considered for trials investigating immediate vs delayed therapy.
Timing and type of HSCT in CR1
The aggressive and systemic nature of MCL argues in favor of implementing aggressive therapeutic strategies in the frontline setting. Despite the lack of a survival benefit in randomized studies, we do recommend high-dose chemotherapy and auto-HSCT in the fit patients with chemosensitive disease. This is based on the observations from phase II studies that showed better outcome compared with patients who did not undergo such procedure. 59, 11 In addition, the Nordic study recently reported suggested a plateau in patients who did not relapse within 4 years from auto-HSCT. 10 Furthermore, Dreyling et al. 52 showed in a randomized trial that early intensification improved PFS when compared with no HSCT. 52 In addition, registry retrospective analysis suggested that HSCT in CR1 might be superior to HSCT in CR2 or beyond. 49 Finally, other studies in relapsed disease showed that patients who undergo HSCT in CR2 or in the refractory setting might have an inferior outcome.
Despite a proven graft-versus-lymphoma effect in many studies, the toxicity of allo-HSCT and the lack of donors for all patients prohibit recommending this procedure for Figure 1 Proposed approach to MCL patients. PS, performance status;
RIC, reduced-intensity conditioning.
Transplantation in mantle cell lymphoma C Nabhan et al all individuals. Furthermore, there is no evidence that such a high-risk procedure provides patients with a survival benefit. Accordingly, we recommend reserving allo-HSCT for fit good performance status patients who have failed previous auto-HSCT and who have a donor.
Conclusions and future directions
With the availability of newer therapies that have shown enhanced efficacy in MCL, the role of HSCT remains controversial and not clearly defined. Individualizing therapeutic approaches is essential to improving outcome in this aggressive disease. Most studies that analyzed the role of HSCT in MCL were single-center trials with small number of patients. There is no agreed upon uniform approach for MCL and clinical trials should always be recommended. 60 We propose considering the MIPI in the decision making. Patients with high MIPI score who are fit otherwise and show chemotherapy-sensitive disease should be considered for early auto-HSCT. However, patients who have low-risk disease could possibly be observed without HSCT; thus, reserving this modality until first relapse. A valid alternative view, given the high degree of safety of autotransplantation today, would be to consider autotransplantation for all patients in first CR unless there is high-risk disease. Patients in first CR with high-risk features or patients failing to attain a CR with CIT should be considered for allo-HSCT. Other variables that could be considered in making HSCT decision can be the Ki-67 index and the balstoid variant of this disease. Figure 1 summarizes our recommendations on how to approach MCL patients and where to position HSCT. We acknowledge that there are many approaches and that ours is a proposed strategy based on current evidence.
